A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).

Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N

Open source

DOI: 10.1016/j.ijgc.2025.102654
Published: 2026 Jun
Container: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2025.102654,
  title = {A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).},
  author = {Eskander RN and Corr B and Cibula D and Tan DSP and Cloven N and Guerra E and Hasegawa K and Myers T and You B and Makker V and Zagouri F and Gien LT and Bartoletti M and Mallen A and Woelber L and Mocci S and Komatsubara K and Ma L and Colombo N},
  year = {2026},
  journal = {International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  doi = {10.1016/j.ijgc.2025.102654},
  url = {https://doi.org/10.1016/j.ijgc.2025.102654}
}

RIS

TY  - JOUR
TI  - A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).
AU  - Eskander RN
AU  - Corr B
AU  - Cibula D
AU  - Tan DSP
AU  - Cloven N
AU  - Guerra E
AU  - Hasegawa K
AU  - Myers T
AU  - You B
AU  - Makker V
AU  - Zagouri F
AU  - Gien LT
AU  - Bartoletti M
AU  - Mallen A
AU  - Woelber L
AU  - Mocci S
AU  - Komatsubara K
AU  - Ma L
AU  - Colombo N
PY  - 2026
JO  - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
DO  - 10.1016/j.ijgc.2025.102654
UR  - https://doi.org/10.1016/j.ijgc.2025.102654
ER  -

APA

RN, E., B, C., D, C., DSP, T., N, C., E, G., K, H., T, M., B, Y., V, M., F, Z., LT, G., M, B., A, M., L, W., S, M., K, K., L, M., & N, C. (2026). A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. https://doi.org/10.1016/j.ijgc.2025.102654

Source records

pubmed · retrieved 2026-09-26T13:33:33.908Z